Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Rated "Buy" by Sell-Side Brokerages

Protagonist Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly bullish: All 17 covering firms rate Protagonist Therapeutics a Buy or Strong Buy, with an average 12-month price target of $166.67.
  • Quarterly results topped estimates: The company reported earnings of $3.07 per share versus $2.50 expected, and revenue of $274.41 million versus $238.49 million forecast.
  • Insiders have been selling shares: Company insiders sold 186,347 shares worth about $26.9 million over the last 90 days; insiders retain 5.19% ownership.
  • Five stocks to consider instead of Protagonist Therapeutics.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been assigned a consensus rating of "Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat reports. Sixteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $166.67.

Several equities research analysts have issued reports on PTGX shares. Truist Financial raised their target price on Protagonist Therapeutics from $145.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. TD Cowen lifted their target price on Protagonist Therapeutics from $155.00 to $160.00 and gave the company a "buy" rating in a research report on Wednesday, October 21st. Citigroup upped their price target on Protagonist Therapeutics from $175.00 to $182.00 and gave the company a "buy" rating in a research note on Monday, August 31st. HC Wainwright increased their price target on Protagonist Therapeutics from $170.00 to $221.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Finally, Wolfe Research reiterated an "outperform" rating on shares of Protagonist Therapeutics in a report on Monday, August 31st.

Read Our Latest Research Report on PTGX

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of Protagonist Therapeutics stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the completion of the sale, the chief executive officer directly owned 522,968 shares in the company, valued at $75,359,688.80. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Arturo Molina sold 2,718 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $124.65, for a total transaction of $338,798.70. Following the sale, the insider owned 81,397 shares of the company's stock, valued at approximately $10,146,136.05. This represents a 3.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 186,347 shares of company stock worth $26,891,786. Company insiders own 5.19% of the company's stock.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. increased its holdings in Protagonist Therapeutics by 2.7% in the 3rd quarter. American Century Companies Inc. now owns 614,732 shares of the company's stock valued at $86,610,000 after purchasing an additional 16,132 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Protagonist Therapeutics in the third quarter valued at approximately $742,000. Advisors Asset Management Inc. acquired a new position in Protagonist Therapeutics during the third quarter worth $285,000. Zacks Investment Management acquired a new position in Protagonist Therapeutics during the third quarter worth $4,100,000. Finally, Algert Global LLC lifted its stake in Protagonist Therapeutics by 119.9% during the third quarter. Algert Global LLC now owns 192,814 shares of the company's stock worth $27,166,000 after purchasing an additional 105,116 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $121.40 on Friday. The firm has a 50 day simple moving average of $138.14 and a 200-day simple moving average of $120.16. The stock has a market cap of $7.92 billion, a price-to-earnings ratio of 25.72 and a beta of 1.21. Protagonist Therapeutics has a 1-year low of $77.00 and a 1-year high of $160.81.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. The firm had revenue of $274.41 million for the quarter, compared to analyst estimates of $238.49 million. Equities analysts expect that Protagonist Therapeutics will post 5.52 earnings per share for the current fiscal year.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

See Also

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Protagonist Therapeutics Right Now?

Before you consider Protagonist Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.

While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines